KYMR ▲ +3.1% - Kymera Therapeutics, Inc.
$KYMR u/g Outperform @ Wolfe pt 180
Kymera Therapeutics rose 3.1% after Wolfe Research upgraded the stock to Outperform with a $180 price target. The upgrade appeared to drive investor buying in the small-cap biotech name.
10-SEP-2026 05:34 AM ET
Share this post
More filings for $KYMR
KYMR - Kymera Therapeutics, Inc. - SEC Filing Update (08-SEP-2026) | ThinkSabio - Stocks SimplifiedSep 8, 2026KYMR ▼ -0.3% - Kymera Therapeutics, Inc.Sep 2, 2026KYMR ▼ -0.6% - Kymera Therapeutics, Inc.Sep 1, 2026KYMR - Kymera Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026KYMR - Kymera Therapeutics, Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026$KYMR SEC Filing Update (26-JUN-2026) | ThinkSabio - Stocks SimplifiedJun 26, 2026
View full $KYMR filing history →💬 Comments
Loading comments…
Leave a comment